Skip to main content
Premium Trial:

Request an Annual Quote

Euro Science Network Wins $44.5M in Funding

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A European science networking and collaboration organization that supports life sciences, molecular biology, and a wide range of other research areas will receive €30 million ($44.5 million) in new funding from the European Commission.

The new funding brings the total EC backing for the European Cooperation in Science and Technology (COST) to €240 million under the EU Seventh Framework Programme (which runs from 2007 to 2013), and the EU may provide COST an additional €10 million depending on budget developments.

COST helps intergovernmental research facilities, institutes, universities, as well as private industry, work together on a wide range of research and development efforts, and includes 250 research networks in 36 countries.

COST's Biomedicine and Molecular Biosciences (BMBS) programs include support for networks in all areas of genomics, proteomics, and metabolomics, and in a range of areas beyond human studies, including plants, viruses, microorganisms, and animals. These BMBS research networks include studies of genome and protein structure and function, lipids, the central nervous system, contagious diseases, cellular research, and tropical diseases.

These studies also include efforts to develop new medical devices and new medicines, nanomedicine, and advanced medical research on biomaterials.

"This is a clear vote of confidence in COST's governance and our intergovernmental framework's ability to contribute to building a globally competitive [European Research Area]," Ángeles Rodríguez-Peña, president of the COST Committee of Senior Officials, said in a statement.

European Science Foundation CEO Marja Makarow said that the additional funding "reflects the valuable contribution COST can make tomorrow, by enhancing capacity building in Europe."

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.